Alison DeBlois - Nova Leap VP Operations
| NVLPF Stock | USD 0.17 0.01 5.56% |
Insider
Alison DeBlois is VP Operations of Nova Leap Health
| Phone | 902 401 9480 |
| Web | https://novaleaphealth.com |
Nova Leap Management Efficiency
The company has return on total asset (ROA) of (0.0294) % which means that it has lost $0.0294 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.0309) %, meaning that it generated substantial loss on money invested by shareholders. Nova Leap's management efficiency ratios could be used to measure how well Nova Leap manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Manjula Sriram | The Joint Corp | N/A | |
| Jason Greenwood | The Joint Corp | N/A | |
| AC DSc | Ramsay Health Care | 70 | |
| Priscilla Kasenchak | agilon health | 43 | |
| Philip Reger | Oncology Institute | N/A | |
| Ben Shaker | agilon health | 41 | |
| Rakesh MBA | Oncology Institute | N/A | |
| Sharad Mansukani | agilon health | 51 | |
| Clay Richards | agilon health | 45 | |
| PT MBA | Enhabit | N/A | |
| Patricia Maryland | Encompass Health Corp | 67 | |
| Diona CPA | Oncology Institute | 44 | |
| Dan Peoples | Enhabit | N/A | |
| Ravi Sachdev | agilon health | 44 | |
| Matthias Link | Fresenius SE Co | N/A | |
| Theodore Halkias | agilon health | 52 | |
| Mat Varghese | agilon health | N/A | |
| Kah Hong | Ramsay Health Care | 50 | |
| JD Kennedy | InnovAge Holding Corp | 64 | |
| Pablo Pantaleoni | Lifestance Health Group | 36 | |
| Ryan Kubota | InnovAge Holding Corp | N/A | |
Management Performance
| Return On Equity | -0.0309 | |||
| Return On Asset | -0.0294 |
Nova Leap Health Leadership Team
Elected by the shareholders, the Nova Leap's board of directors comprises two types of representatives: Nova Leap inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nova. The board's role is to monitor Nova Leap's management team and ensure that shareholders' interests are well served. Nova Leap's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nova Leap's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Alison DeBlois, VP Operations | ||
| Michael Gremley, Mang Devel |
Nova Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Nova Leap a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0309 | |||
| Return On Asset | -0.0294 | |||
| Profit Margin | (0.02) % | |||
| Operating Margin | (0.04) % | |||
| Current Valuation | 18.18 M | |||
| Shares Outstanding | 86.21 M | |||
| Shares Owned By Insiders | 36.06 % | |||
| Price To Earning | 10.57 X | |||
| Price To Book | 1.12 X | |||
| Price To Sales | 0.79 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Nova OTC Stock
Nova Leap financial ratios help investors to determine whether Nova OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nova with respect to the benefits of owning Nova Leap security.